Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Immunogenicity of HLX05 vs. Erbitux in Healthy Chinese Males
NCT06309043Phase 1Active, not recruiting
- Sponsor
- Henlius
- Start
- Apr 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of HLX05 in colorectal cancer (CRC) and head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by Henlius. Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Infinity. Started Apr 2024; status: active, not recruiting.
02
Drugs
HLX05
03
Conditions
colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06309043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06309043.